Welcome to our dedicated page for Replimune Group SEC filings (Ticker: REPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Replimune Group, Inc. filings document regulatory, financing, governance and operating disclosures for a Nasdaq-listed clinical-stage biotechnology company focused on oncolytic immunotherapies. Recent Form 8-K reports cover FDA communications involving the RP1 Biologics License Application, including complete response letters and related Regulation FD disclosures.
The filing record also documents quarterly financial results, corporate presentation materials for RP1 and RP2 programs, amendments to the company’s loan and security agreement, and annual meeting voting results. These disclosures describe Replimune’s development-stage operating profile, capital structure arrangements, stockholder governance matters and material events tied to its cancer immunotherapy pipeline.
Replimune Group director Kapil Dhingra received a grant of stock options covering 44,500 shares of Common Stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. All underlying shares vest together on April 1, 2027, and no open-market buy or sell occurred.
Replimune Group, Inc. director Paolo Pucci received a grant of stock options covering 44,500 shares of Common Stock. The options have a per-share exercise price of $7.61 and expire on April 1, 2036. All underlying shares vest in a single tranche on April 1, 2027. This is a compensation-related award rather than an open-market purchase or sale, and after this grant Pucci holds 44,500 stock options directly.
Replimune Group, Inc. director Joseph P. Slattery received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. According to the disclosure, all 44,500 underlying shares vest in full on April 1, 2027. Following this grant, Slattery holds 44,500 stock options directly.
Replimune Group, Inc. director Veleka Peeples-Dyer received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. All underlying shares vest on April 1, 2027, making this a compensation-related, non-market transaction.
Replimune Group, Inc. Chief Financial Officer Emily Luisa Hill reported receiving new equity awards. She was granted an employee stock option for 75,000 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. Twenty-five percent of this option vests on April 1, 2027, with the rest vesting in 36 approximately equal monthly installments.
Hill was also granted 50,000 restricted stock units (RSUs), each representing one share of common stock. Twenty-five percent of these RSUs vest on May 15, 2027, with the remainder vesting in three approximately equal annual installments until May 15, 2030, subject to continued service. Following the RSU grant, her direct common stock holdings increased to 244,368 shares.
Replimune Group, Inc. director Weinand Dieter received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036.
According to the filing, these options vest in full on April 1, 2027. Following this grant, Dieter holds 44,500 derivative securities directly, reflecting a compensation award rather than an open-market purchase.
Replimune Group, Inc. Chief Commercial Officer Christopher Sarchi sold 6,500 shares of common stock in an open-market transaction. The shares were sold on April 2, 2026 at a weighted average price of $8.01 per share, in multiple trades between $8.00 and $8.06.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025, indicating it was scheduled in advance. After this sale, Sarchi beneficially owns 151,588 shares of Replimune common stock, including restricted stock units, and holds options to acquire an additional 250,425 shares, 142,555 of which are currently exercisable.
REPL filed a Form 144 notice relating to proposed sales of Common shares. The filing lists a broker-dealer, J.P. Morgan Securities LLC, and includes a filing date of 04/02/2026. The excerpt shows scheduled RSU vesting entries on 11/15/2023, 11/15/2024, and 11/15/2025 with specified share amounts.
Replimune Group, Inc. director Philip Astley-Sparke reported a disposition of shares through a bona fide gift. He transferred 25,000 shares of Common Stock at a reported price of $0.00 per share, characterized as a gift transfer.
After this transaction, his directly held ownership was reported as 1,380,071 shares of Common Stock. The filing reflects a charitable or personal transfer rather than an open-market sale, so it does not indicate cash proceeds to the director.
Forbion Capital Fund III Cooperatief U.A. and Forbion III Management B.V. report their current ownership in Replimune Group, Inc. common stock. They beneficially own 2,808,368 shares, representing about 3.5% of the company’s outstanding common stock.
This percentage is based on 79,631,167 Replimune shares outstanding as of December 31, 2025, and reflects that the Reporting Persons now hold 5% or less of the class. All voting and investment power over these shares is shared, with no sole voting or dispositive authority reported.